Analysts Set INmune Bio, Inc. (NASDAQ:INMB) Price Target at $8.00

INmune Bio, Inc. (NASDAQ:INMB) has received a consensus rating of “Hold” from the six research firms that are covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation, one has issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $8.00.

INMB has been the topic of a number of recent analyst reports. Lucid Cap Mkts upgraded INmune Bio from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, March 11th. Wall Street Zen upgraded INmune Bio from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th.

INmune Bio Stock Performance

Shares of INMB stock opened at $1.51 on Monday. The firm has a market cap of $40.14 million, a P/E ratio of -0.79 and a beta of 1.04. INmune Bio has a fifty-two week low of $1.09 and a fifty-two week high of $11.64. The business’s 50 day moving average price is $1.30 and its 200-day moving average price is $1.54.

INmune Bio (NASDAQ:INMB) last issued its quarterly earnings data on Monday, March 30th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.09.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Quadrature Capital Ltd purchased a new position in INmune Bio during the fourth quarter valued at $26,000. Intech Investment Management LLC purchased a new position in INmune Bio during the second quarter valued at $26,000. Cary Street Partners Financial LLC purchased a new position in INmune Bio during the third quarter valued at $29,000. Independent Advisor Alliance purchased a new position in INmune Bio during the third quarter valued at $30,000. Finally, Squarepoint Ops LLC purchased a new position in INmune Bio during the third quarter valued at $30,000. Hedge funds and other institutional investors own 12.72% of the company’s stock.

About INmune Bio

INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company’s research and development efforts concentrate on modulating cellular pathways to restore and enhance the body’s natural defenses, particularly in oncology and neurodegenerative conditions.

The company’s lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions.